Yükleniyor... / Loading...
This study examined the cancer genome using samples from patients with high-grade osteosarcoma (a bone cancer) treated with famitinib and camrelizumab. Patients with chemotherapy-refractory osteosarcoma who had tissue samples before treatment and after progression were included. The study had no assigned phase and has been completed.
The summary above is a plain-language rendering of the official record. The original English title is shown for reference.
Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.
Inclusion Criteria: * Diagnosis of high-grade osteosarcoma * refractory to chemotherapy and intended to receive famitinib and camrelizumab following the protocols of SHR1020-SHR-1210-II-OS * Available tumor tissue samples collected before study drug and after first progression * Must have matching frozen samples of normal tissue and blood Exclusion Criteria: * Patients with concurrent malignancy; patients with prior or concurrent malignancy will be allowed as long as the treating physician considers it unlikely to impact the clinical outcome of the patient * Serious medical illness including but not limited to uncontrolled congestive heart failure, uncontrolled angina, myocardial infarction or cerebrovascular event with 6 months of registration, history of chronic active hepatitis or history of human immunodeficiency virus (HIV) or an active bacterial infection will not be eligible * Pregnant or lactating women